Loading...
•
Sep 30, 2023
OPKO Health Q3 2023 Earnings Report
Reported business highlights and financial results for Q3 2023.
Key Takeaways
OPKO Health reported consolidated total revenues of $178.6 million, compared to $179.7 million for the comparable 2022 period. The operating loss was $64.4 million for the third quarter of 2023, compared to an operating loss of $87.8 million for the 2022 quarter. Net loss for the third quarter of 2023 was $84.5 million, or $0.11 per share, compared with a net loss of $86.1 million, or $0.11 per share, for the 2022 quarter.
ModeX Therapeutics received a BARDA contract to develop multispecific antibodies against viral infectious disease threats.
NGENLA is now approved in 48 markets, with sales underway by Pfizer in over 23 countries.
New clinical data on RAYALDEE was presented at Kidney Week 2023, indicating slower progression of chronic kidney disease with early treatment.
BioReference Health continued its plan to improve operational efficiencies and enhance productivity, aiming to return to profitability.
Forward Guidance
OPKO’s senior management will provide a business update, discuss third quarter financial results, provide financial guidance and answer questions during a conference call and audio webcast today beginning at 4:30 p.m. Eastern time.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...